PlushCare Ozempic Cost: What You Actually Pay, With and Without Insurance

What does Ozempic actually cost through PlushCare?

Run the numbers two ways, because PlushCare genuinely produces two different bills depending on one variable: does your insurance plan cover Ozempic for the reason you're seeing a doctor? If it does, a realistic year of care lands somewhere between $500 and $1,300 — mostly copays, plus an optional membership if you choose one. If it doesn't, PlushCare's cash-pay route through Novo Nordisk's own NovoCare Pharmacy program realistically runs $4,700 to $5,800 for the year — well above the flat rate a compounded-only telehealth brand like Mochi Health advertises, because PlushCare doesn't sell compounded semaglutide at all. For the full landscape of what semaglutide costs across every channel, brand and compounded, see semaglutide cost.

Month to month, that split looks like this. With accepted insurance, the visit itself is often a copay of $30 or less, and the medication copay for Ozempic — assuming your plan covers it — commonly falls between $25 and $75. Without insurance, the first visit runs $129, follow-ups run less, and the medication is priced through PlushCare's NovoCare discount path at $199 for the first two months, then $399 to $499 depending on dose. Full retail without any discount card at all — the price a pharmacy charges if you walk in with nothing — sits closer to $950 to $1,200 a month, which is why almost nobody actually pays that number.

The gap between those two paths is the whole story with PlushCare. It isn't a pricing gimmick so much as a structural fact of how the company works: it bills like a primary-care practice, because that's what it is.

Will insurance actually cover Ozempic here — or does PlushCare just mean "we accept your card"?

This is the question worth sitting with before you book anything. PlushCare is in-network with most major carriers — Aetna, Blue Cross Blue Shield, Anthem Blue Cross, Blue Shield of California, Cigna, Humana, Tricare, and Medi-Cal all show up on its accepted list. That's real, and it means the appointment itself is usually cheap. But being in-network for the visit and having your insurance pay for Ozempic are two separate promises, and PlushCare's own site is honest about the reason: Ozempic is FDA-approved for type 2 diabetes. Semaglutide's weight-management approval exists under a different brand name, Wegovy, at a different dose. PlushCare's materials reflect that distinction directly — a patient coming in purely for weight loss is generally routed toward Wegovy or Zepbound rather than an off-label Ozempic prescription.

For insurance purposes, that distinction matters more than almost anything else on this page. Most commercial plans that cover Ozempic require a type 2 diabetes diagnosis on the claim. Coverage for Ozempic prescribed off-label for weight loss, without that diagnosis, is inconsistent across insurers and frequently denied or held up in prior authorization, sometimes for several business days. Wegovy coverage for weight management is a separate approval question with its own plan-by-plan variability. Even the manufacturer's own savings card only helps if you already have qualifying commercial insurance — the NovoCare card caps the Ozempic copay around $25, but it explicitly excludes Medicare, Medicaid, and Tricare, and it requires insurance in place to begin with. None of this makes PlushCare's insurance acceptance false advertising. It means the honest reading of "PlushCare accepts your insurance" is "your visit will likely be affordable," not "your Ozempic prescription is covered." Those are different sentences, and confusing them is where the surprise bills start.

The PlushCare visit fee — what it covers, and the membership tier

Strip away the medication question and PlushCare's underlying fee structure is fairly plain. A visit with insurance typically costs whatever your plan's copay is — commonly $30 or less for an in-network specialist or primary-care visit, though this varies by plan. Without insurance, the first visit is $129 and follow-up visits run somewhat less. That fee covers the actual clinical work: a licensed physician reviewing your history, discussing options, and writing a prescription if appropriate — not a subscription, not a retainer.

Separately, PlushCare offers an optional membership at $19.99 a month, with the first month free. This is worth pausing on, because it's a genuine structural difference from most of its GLP-1-focused competitors. At Ro and Hers, a membership fee is mandatory just to access prescribing at all — $145 and $149 a month, respectively, billed regardless of what medication you're on. At PlushCare, the membership buys faster scheduling, unlimited in-app messaging with your care team, and discounts on labs and prescriptions, but you can see a doctor and receive a prescription without ever signing up for it, paying per-visit instead. For a woman who just wants an occasional check-in rather than an always-on care relationship, skipping the membership is a legitimate way to keep the annual total down.

How much is Ozempic without insurance through PlushCare?

If your plan won't cover Ozempic, PlushCare doesn't just leave you at the pharmacy counter facing a four-figure bill — it routes cash-pay patients through NovoCare Pharmacy, Novo Nordisk's own direct-to-patient program. That pricing starts at $199 a month for the first two months at the two lowest starting doses, then steps up to $399 or $499 a month depending on which dose you land on. It's a real discount off the roughly $950 to $1,200 a month that Ozempic costs at full, undiscounted retail — but it's still a meaningfully bigger number than the flat $99-to-$297-a-month pricing that compounded-first competitors advertise, because those platforms are selling a different, unbranded product made by a compounding pharmacy rather than Novo Nordisk's own manufactured drug.

That tradeoff is the honest one to weigh. PlushCare's cash price buys you the actual FDA-approved, brand-name drug, manufactured under Novo Nordisk's own quality oversight. A compounded semaglutide platform buys you a chemically similar product at a lower, flatter monthly rate, made under a different regulatory framework. Neither is inherently wrong; they're different products at different price points, and which one is right depends on your priorities and your budget.

Hidden costs to plan for

• Labs at intake and six months: PlushCare requires baseline bloodwork when you start and again at the six-month mark, run through Quest Diagnostics at a discounted self-pay rate of roughly $15 per marker set — not free, even though it's cheaper than a standard lab bill
• Prior authorization delays: if your insurer requires prior auth for Ozempic or Wegovy, expect the approval process to take several business days, during which you're either waiting or paying cash to bridge the gap
• Follow-up visit fees: refill and dose-adjustment visits carry their own fee (copay if insured, roughly $99 cash if not) — these add up if your dose changes more than once or twice a year
• Dose-dependent pricing: PlushCare's cash and NovoCare-discounted prices both rise as your prescribed dose increases, so the starter-dose number quoted on the site is a floor, not a ceiling
• The optional membership, if you take it: $19.99 a month is easy to forget you're paying if you signed up for the free trial and didn't cancel
• FSA/HSA can offset some of this: visits, medication, and labs are all eligible for FSA/HSA payment, which effectively discounts the after-tax cost by roughly 20 to 30 percent depending on your bracket

If Ozempic doesn't get approved, what are the PlushCare alternatives?

PlushCare's own answer to a denied or unlikely Ozempic approval is to pivot you toward the on-label weight-management drug instead. Wegovy — the same active molecule, semaglutide, at a higher dose approved specifically for weight loss — is priced identically to PlushCare's Ozempic cash path: $199 a month for the first two months, then roughly $399 ongoing. Zepbound, tirzepatide from Eli Lilly, is also available, running from $299 a month at the starter 2.5 mg dose up to $449 at higher maintenance doses. Both are real, FDA-approved options, and both are more likely to see insurance coverage for a weight-loss indication than off-label Ozempic ever will be, since they're approved for exactly that use.

If none of that pencils out — if your insurer won't cover any GLP-1 for weight management and the cash prices above are simply more than you want to spend — it's worth looking beyond PlushCare rather than forcing the fit. A brand-name-only, insurance-adjacent platform like Ro offers a similar structure with more membership-included services (labs, coaching, prior-auth help) at a higher fixed cost. A cash-pay platform like Hers sells brand-name Wegovy and Zepbound with no insurance angle at all, which simplifies the math even if it doesn't lower it. Either can be a more honest fit than staying on a coverage path that keeps stalling.

PlushCare vs Ro, Hers, Mochi Health, and Henry Meds — how the cost model actually differs

Line these up side by side and the real differentiator isn't the sticker price — it's what kind of company is setting it, and what you're actually buying.

• PlushCare: insurance-first primary care. No mandatory membership, visit copays as low as $30 if in-network, but Ozempic itself is only cheap when your plan covers it — cash-pay runs $399–$499/mo ongoing through NovoCare
• Ro: brand-name-only, membership-included model — $145/mo membership ($45 first month) plus $149–$449/mo medication, all-in $294–$594/mo, with labs and insurance navigation bundled in regardless of coverage outcome
• Hers: brand-name GLP-1s with a separate mandatory membership — $149/mo membership plus $149–$299+/mo medication, all-in roughly $298–$348/mo for the lower-cost Wegovy options, cash-pay only, no insurance angle at all
• Mochi Health: compounded semaglutide at a flat rate regardless of dose — $79/mo membership plus $99/mo medication, about $178/mo all-in, the cheapest of this group but not a brand-name or insurance-billed product
• Henry Meds: compounded semaglutide or tirzepatide, one all-in monthly fee with no separate membership — $249/mo for oral semaglutide up to $449/mo for injectable tirzepatide, cash-pay only

The pattern: Ro and Hers charge more but remove ambiguity — you know your all-in cash price up front, insurance or not. Mochi Health and Henry Meds are cheaper still, trading brand-name and insurance billing for a compounded product and a flat rate. PlushCare is the only one of the five where your actual cost is genuinely unknowable until your insurance company weighs in — which is either the best deal in the group or one of the more expensive, depending entirely on what your plan decides.

What a full year of Ozempic through PlushCare really adds up to

With coverage that includes Ozempic: figure roughly $120 to $180 a year in visit copays across an initial visit and a few refill check-ins, plus $300 to $900 a year in medication copays at a typical $25-to-$75-a-month range. Skip the optional membership and you're at roughly $500 to $1,100 for the year; add it and you're closer to $700 to $1,300. That's the scenario PlushCare is quietly built around, and it's genuinely competitive with anything else on this list when it works.

Without coverage: the first visit and a couple of follow-ups run around $330 for the year, and the NovoCare-discounted medication — $199 for two months, then $399 to $499 for the remaining ten — lands between roughly $4,400 and $5,400. Add the visit costs and a full cash-pay year through PlushCare comes to somewhere between $4,700 and $5,800. That's real money, and it's higher than what you'd pay for a full year of compounded semaglutide through Mochi Health (about $2,136 a year) or Henry Meds (roughly $3,000 to $5,400 a year depending on form). It is, however, a brand-name, FDA-manufactured drug rather than a compounded one, which is the trade you're making for that premium.

Is PlushCare worth it for Ozempic?

For the woman it's actually built for — already insured, likely carrying a metabolic diagnosis alongside perimenopause, and looking for a GLP-1 conversation that doesn't require joining a separate weight-loss startup — PlushCare is a genuinely good fit. The company itself isn't the risk here: it's been operating since 2014, was acquired by Accolade for $450 million in 2021, holds an A rating with the Better Business Bureau, and has no FDA warning letter on its record, which sets it apart from more than one compounded-GLP-1 competitor. A 2021 class-action settlement over subscription auto-renewal disclosures is on the books, but it's resolved, and the company updated its billing language as a result. The membership being optional, rather than mandatory, is a real point in its favor.

The one reservation worth carrying into your first visit is the coverage question, and it deserves proportionate weight rather than alarm: insurance acceptance at PlushCare means your appointment is affordable, not that Ozempic specifically is guaranteed to be covered or even the medication you'll walk away with. If you're coming in hoping for off-label Ozempic coverage without a diabetes diagnosis, expect PlushCare to steer you toward Wegovy instead, and expect the cash-pay numbers above to apply if your plan ultimately says no. Go in knowing which scenario you're likely to land in, and PlushCare is hard to fault.